CRISPR Therapeutics AG (CRSP) Net Margin (2016 - 2026)
CRISPR Therapeutics AG (CRSP) posted Net Margin of 8431.48% for Q1 2026, up 55.1% sequentially from 18778.36% in Q4 2025, and up 728956.0% YoY from N/an in Q1 2025.
CRISPR Therapeutics AG (CRSP) Net Margin (2016 - 2026) Analysis & Trends
CRISPR Therapeutics AG has reported Net Margin for 11 years, with the latest figure at 8431.48% in Q1 2026.
- Quarterly Net Margin rose 728956.0% year-over-year to 8431.48% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 14627.49% (down 1467590.0% YoY) and the FY2025 annual result came in at 17470.4%, down 1757129.0% from the prior year.
- Net Margin grew to 8431.48% in Q1 2026 per CRSP's latest filing, from 18778.36% in the prior quarter.
- Over five years, Net Margin peaked at 1027.11% in Q4 2024 and troughed at 1842916.67% in Q4 2022.
- A 5-year average of 144032.27% and a median of 17249.7% in 2025 frame the typical range for Net Margin.
- The sharpest annual moves came in 2022 and 2023: Net Margin slumped 184182164 bps in 2022, then jumped 184296109 bps in 2023.
- Over 5 years, Net Margin stood at 1842916.67% in 2022, then soared by 100 bps to 44.43% in 2023, then jumped by 2212 bps to 1027.11% in 2024, then slumped by 1928 bps to 18778.36% in 2025, then surged by 55 bps to 8431.48% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 8431.48%, 18778.36%, and 11973.12% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | CRISPR Therapeutics AG | 5.18 Bn | 5.18 Bn | - | -895.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -895.73% |
| Mar 31, 2026 | -8,431.48% |
| Dec 31, 2025 | -18,778.36% |
| Sep 30, 2025 | -11,973.12% |
| Jun 30, 2025 | -23,379.93% |
| Mar 31, 2025 | -15,721.04% |
| Dec 31, 2024 | 1,027.11% |
| Sep 30, 2024 | -14,276.08% |
| Jun 30, 2024 | -24,452.80% |
| Mar 31, 2024 | -23,133.13% |
| Dec 31, 2023 | 44.43% |
| Jun 30, 2023 | -111.06% |
| Mar 31, 2023 | -53.07% |
| Dec 31, 2022 | -1,842,916.67% |
| Sep 30, 2022 | -185,690.43% |
| Jun 30, 2022 | -117,605.06% |
| Mar 31, 2022 | -19,065.64% |
| Dec 31, 2021 | -1,095.03% |
| Sep 30, 2021 | -15,430.58% |
| Jun 30, 2021 | 84.29% |